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Open access under the ElseviNitric oxide (NO) is a potent vasodilator and it can be generated by the ruthenium complex cis-[Ru(H-
dcbpy)2(Cl)(NO

2 )] (DCBPY). The present study aimed to investigate the NO specie generated and to
characterize the cellular mechanisms involved on the vasodilatation induced by DCBPY. It was found that
at pH 7.4 and 9.4, the NO+ coordinated to ruthenium (Ru-NO+) is converted to NO2 (Ru-NO

2 ), which
remains stable. However, the conﬁguration Ru-NO+ is stable at pH 5.4. It was also veriﬁed that the DCBPY
complex (Ru-NO2 conﬁguration) induces vascular relaxation of contracted rat aortic rings in a concentra-
tion-dependent manner. Therefore, the potency (pD2 values) and the maximum relaxant effect (ME) were
compared. It was observed that relaxation is more pronounced to Ru-NO+ conﬁguration, compared with
Ru-NO2 , with no difference in ME. On the other hand, the potency of DCBPY (Ru-NO

2 ) is lower than that
of SNP and higher than that of NITRITE, with no difference in ME for all the compounds. Further exper-
iments were conducted using DCBPY in the Ru-NO2 conﬁguration. It was noted that the relaxation
induced by DCBPY is completely blocked by the soluble guanylyl cyclase (sGC) enzyme inhibitor. The
non-selective K+ channel blocker (TEA) diminishes the potency of DCBPY, but it does not change the
ME. Incubation with selective radicalar NO (NO) and extracellular NO scavengers almost abolishes the
relaxation induced by DCBPY. The use of a selective nitroxyl (NO) scavenger decreases the potency of
DCBPY, but it does not alter the ME. By using confocal microsopy, it was found that DCBPY, SNP, and
NITRITE raise the cytosolic NO concentration and reduce the cytosolic Ca2+ concentration [Ca2+]c in rat
aortic smooth muscle cells. These effects are not different when DCBPY and SNP are compared, but they
are lower for NITRITE. Taken together, our results demonstrate that the compound DCBPY (Ru-NO2 ) is an
NO generator that promotes relaxation of rat aortic rings due to a reduction in [Ca2+]c. The vascular
smooth muscle relaxation is dependent on sGC activation.
 2011 Elsevier Inc. Open access under the Elsevier OA license.Introduction
Nitric oxide (NO) is a simple diatomic molecule that has been
shown to participate in many important biological events,
including vascular smooth muscle relaxation [1,2], inhibition of
smooth muscle proliferation, and platelet aggregation [4]. The vas-
cular relaxation induced by NO mainly involves the activation of
soluble guanylyl cyclase (sGC) enzyme with production of cyclic
guanosine-30,50-monophosphate (cGMP) [4]. NO can also prompt
vascular relaxation by an independent cGMP pathway, via direct
activation of K+ channels [5,6]. Several studies have suggested thatFarmacologia, Faculdade de
v. do Café s/no. 14040-903
.
er OA license.the mechanism of vascular relaxation varies for different NO do-
nors, mainly in terms of the degree of activation of sGC and/or acti-
vation of K+ channels [7,8].
NO is highly reactive molecule that reacts with a range of bio-
molecules, including metal center, thiols, superoxide and others,
conferring to NO a short half-life in physiological conditions [9].
Basal NO synthesis; i.e., generation of NO at low concentration, is
necessary to establish homeostasis of the cardiovascular system
[3]. Decreased NO bioavailability has been described in cardiovas-
cular disorders, such as hypertension and coronary disease [3].
Therefore, the use of NO donors could be a therapeutic alternative
to NO failure.
Organic nitrates (e.g., Nitroglicerin, TNG) as well as inorganic
nitrates (e.g., sodium nitroprusside, SNP) have been employed in
the treatment of various cardiovascular disorders. However, there
are many limitations to their use, and both classes of compounds
332 G.J. Rodrigues et al. / Nitric Oxide 25 (2011) 331–337have undesirable side effects [10]. Continuous exposure to TNG
leads to the development of nitrate tolerance [10] and endothelial
dysfunction [11]. High doses of SNP or its prolonged use has been
associated with endothelial dysfunction [13], as well as accumula-
tion of cyanide and the metabolite thiocyanate [12]. Therefore, the
design of new NO donors with better pharmacological properties is
highly desirable.
Macrocyclic ruthenium compounds have been investigated as
NO donors [14–17] and they have not displayed any toxic effects.
These compounds have been found to induce vasodilatation in
physiological conditions [17–19] and reduce blood pressure in
hypertensive animals [20]. The conﬁgurations of the ruthenium
ion are very useful due to their rich and versatile redox chemistry,
in addition to their favorable thermodynamic and kinetic proper-
ties. However, there is a limiting factor in physiological conditions,
namely the tendency of the NO coordinated to ruthenium (Ru-NO+)
to undergo electrophilic attack by hydroxide or water, which
results in the production of Ru-NO2 nitro analog species [21]. De-
spite the formation of the latter species, some studies have shown
that it can generate NO [22,23]. Several works have reported mech-
anisms of in vivo conversion of NO2 to NO by non-enzymatic
disproportionation at low pH [24], xanthine oxidoreductase [25],
deoxyhemoglobin [26], myoglobin [27], among others. In this
context, the present study aimed to investigate the NO specie
generated and to characterize the cellular mechanisms involved
on the vasodilatation induced by the new ruthenium complex
cis-[Ru(H-dcbpy)2(Cl)(NO)] (Fig. 1A), which can generate NO.Fig. 1. Representative spectrum of the compound cis-[Ru(dcbpy)2(Cl)(NO)] solubilized
Structure of compound cis-[Ru(H-dcbpy)2(Cl)(NO

2 )]. (B) Compound solubilized at pH 7
experiment was carried out at least three times, and the same results were veriﬁed in aMethods
Synthesis of cis-[Ru(H-dcbpy)2(Cl)(NO)]
The cis-[Ru(H-dcbpy)2(Cl)(NO)] (DCBPY) complex was
prepared as described by Cicillini et al. [28], where the ligand H2-
dcbpy is: 4,40-dicarboxy-2,20-bipyridine. To this end, cis-[Ru(H2-
dcbpy)2Cl2]2H2O (0.100 g, 0.14 mmol) was dissolved in distilled
water, and this solution was degassed for 30 min, for oxygen re-
moval. Gaseous NO was generated by reaction between nitric acid
solution (50% v/v) and metallic copper. The produced gaseous mix-
ture was passed through a concentrated NaOH solution, to elimi-
nate traces of NO2 . The obtained nitric oxide was bubbled
through the cis-[Ru(H2-dcbpy)2Cl2]2H2O complex solution for
40 min, and the reaction mixture was stirred for another 6 h. This
procedure was repeated for three times, and a brown precipitate
was formed. The precipitate was collected by ﬁltration, washed
with diethyl ether, and stored under vacuum in the dark. A 73%
yield of cis-[Ru(H-dcbpy)2(Cl)(NO)] was achieved.
Chemical studies for the DCBPY complex
The ultraviolet–visible (UV–Vis) spectra were recorded on a
Hitachi U-3501 spectrophotometer. In all the experiments, the
solution was kept at 37 C and phosphate buffer, namely at pH
5.4, pH 7.4, or pH 9.4. pH measurements were accomplished by
means of a DM-20 pH meter (Digimed).at different pH values, at 37 C. The dashed line represents the ﬁrst spectrum. (A)
.4. (C) Compound solubilized at pH 9.4. (D) Compound solubilized at pH 5.4. Each
ll of them.
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All the procedures were carried out in accordance with the
Guide for the Care and Use of Laboratory Animals published by
the US National Institutes of Health (NIH Publication No. 85-23,
revised 1996) and the standards and policies of the Animal Care
and Use Committee of the University of São Paulo. Male Wistar rats
(180–200 g) were killed under anesthesia, and the thoracic aortas
were isolated, cleaned of adherent connective tissues, and cut into
rings with 4 mm length. The endothelium was mechanically
removed by gently rolling the lumen of the vessel on a thin wire.
The aortic rings were placed between two stainless-steel stirrups
and connected to an isometric force transducer (Letica Scientiﬁc
Instruments; Barcelona, Spain), to measure tension in the vessels.
The rings were settled in a 10 mL organ chamber containing Krebs
solution, which was maintained at pH 7.4 gassed with 95% O2 and
5% CO2 at 37 C. The rings were initially stretched to a basal tension
of 1.5 g and were then allowed to equilibrate for 60 min.
Endothelial integrity was qualitatively assessed by the degree of
relaxation induced by 1 lmol/L acetylcholine in the presence of
contractile tone prompted by phenylephrine (0.1 lmol/L). In order
to avoid interference of the endothelium factors, denuded aortas
were employed. Therefore, the aortic rings were discarded if there
was any degree of relaxation. The potency (pD2, which is the neg-
ative logarithm of the molar concentration producing the half max-
imum relaxant effect) and the maximum relaxant effect (ME, in
percentage of relaxation) were evaluated. Concentration-effect
curves for DCBPY, sodium nitruprusside (SNP), and sodium nitrite
(NITRITE) were constructed for aortic rings pre-contracted with
phenylephrine. In some experiments, the aortic rings were
incubated for 30 min with either the sGC inhibitor 1H-(1,2,4)-oxa-
diazol-(4,3-a)-quinoxalin-1-one (ODQ) or the non-selective K+
channel blocker tetraethylammonium (TEA). Also, the NO scaveng-
ers for extracellular NO oxyhemoglobin (10 lmol/L), for nitroxyl
NO (NO) L-cysteine (1 mmol/L), or for radicalar NO (NO) hydrox-
ocobalamin (100 lmol/L) were utilized.
Prior to its use, the compound DCBPY was prepared in phos-
phate buffer pH 7.4 and kept at 37 C for 180 min. This was done
in order to avoid different conﬁgurations of the compound DCBPY,
and ensure the presence of the conﬁguration Ru-NO2 only. In some
experiments, the compound DCBPY was solubilized at pH 5.4 or pH
9.4 (Fig. 1C and D).
Confocal microscopy
The confocal microscopy experiments were performed as
described by Rodrigues et al. [29]. Rats were killed by decapitation,
and the thoracic aortas were isolated and dissected. The endothe-
lium was mechanically removed by gently rolling the lumen of the
vessel on a thin wire. Cross sections of aortic rings (100–150 lm
thick) were placed vertically on glass coverslips covered with
poly-L-Lysine, in Hanks solution. The slice preparations were kept
for 60 min in a humidiﬁed incubator at 37 C and gassed with 5%
CO2.
To quantify the cytosolic Ca2+ concentration ([Ca2+]c), slice
preparations were loaded with Fluo-3AM (10 lmol/L) for 30 min
at room temperature in Hanks buffer pH 7.4. Excess dye was
removed by washing out the dye with Hanks solution and allowing
30 min for intracellular desesteriﬁcation of Fluo-3AM. To deter-
mine the cytosolic NO concentration ([NO]c), slice preparations
were loaded with the selective NO ﬂuorescent dye (DAF-2/DA
5 lmol/L) for 30 min and maintained in a humidiﬁed 37 C incuba-
tor gassed with 5% CO2.
Slice preparations were imaged in Hanks buffer at pH 7.4, by
using a confocal scanning laser microscope (Leica TCS-SP5).
Fluo-3AM ﬂuorescence was excited with the 488 nm line of an ar-gon ion laser, and the emitted ﬂuorescence was measured at
510 nm. DAF-2/DA ﬂuorescence was excited with 488 nm line of
argon ion laser, and the emitted ﬂuorescence was measured at
515 nm. A time-course software was used to capture the cells
images at 2 s intervals (xyt) in the Live Data Mode acquisition at
1024  1024 pixels, at 700 Hz. Using the LSCM computer software,
the intensity of the intracellular maximum and minimum ﬂuores-
cence was measured in the smooth muscle sliced regions. The ini-
tial ﬂuorescence intensity value was obtained at t = 0 and was
designated F0. The ﬁnal ﬂuorescence intensity value was achieved
after stimulation with DCBPY (10 lmol/L), SNP (0.1 lmol/L), or
NITRITE (300 lmol/L), and it was named F. In this way, the per-
centage of the difference in ﬂuorescence intensity (%DFI), which
reﬂects a reduction in [Ca2+]c and a rise in [NO]c in smooth muscle
cells, was calculated for each protocol in relation to F0 (100%), by
means of the following formula.
%DF ¼ ðF  F0=F0Þ  100Statistical analysis
Data are expressed as mean ± S.E.M. In each set of experiments,
n indicates the number of rats studied. Statistical analysis of the
results was performed by using GraphPad Prism version 3.0. Statis-
tical signiﬁcance was tested by one-way ANOVA (post hoc test:
Newman–Keuls). Values of P < 0.05 were considered signiﬁcant.
Drugs and chemicals
Acetylcholine, phenylephrine, NaNO2, TEA, ODQ, DAF-2/DA, and
Fluo-3AMwere purchased from Sigma–Aldrich (St.Louis, MO, USA).Results
Chemical studies for the compound DCBPY
The ultraviolet–visible (UV–Vis) spectra revealed that the
compound DCBPY can assume different conﬁgurations, which are
pH-dependent, as depicted in Fig. 1B–D. At pH 7.4 and 37 C, the
DCBPY complex (as the Ru-NO+ species, absorbance at 330 nm) is
converted to Ru-NO2 species as a function of time (absorbance
450 nm, Fig. 1B). This change was also followed by fourier trans-
form infrared spectroscopy (FTIR) spectrum where a band at
1930 cm1 attributed to NO coordinated to ruthenium (mNO) disap-
peared completely in basic medium and appeared again in acidic
medium (data not supplied).
At pH 5.4 and 37 C, the Ru-NO+ conﬁguration of the DCBPY
complex is not modiﬁed over the studied period (Fig. 1C). However,
at pH 9.4 and 37 C the compound is converted to the Ru-NO2 con-
ﬁguration, which is not altered up to 60 min (Fig. 1D).
Vascular reactivity studies
The new DCBPY complex induces relaxation of the aortic rings
in a concentration-dependent way, in denuded aortas pre
-contracted with phenylephrine (Fig. 2). The potency of SNP
(pD2: 8.87 ± 0.10, P < 0.001, n = 8) to elicit relaxation is higher than
that of DCBPY (pD2: 5.71 ± 0.06, n = 9), whereas there are no differ-
ences between SNP (101.5 ± 1.3%) and DCBPY (106.1 ± 1.7%) with
respect to the maximum relaxation (Fig. 2).
The DCBPY complex acquires different conﬁgurations at differ-
ent pH values, as demonstrated in Fig. 1. Therefore a comparison
of these different conﬁgurations shows that the compound solubi-
lized at pH 7.4 (pD2: 5.71 ± 0.06, n = 9) presents similar potency of
relaxation compared with the compound prepared at pH 9.4 (pD2:
Fig. 2. Concentration–response curves for cis-[Ru(H-dcbpy)2(Cl)(NO

2 )] (DCBPY)
and sodium nitroprusside (SNP) in endothelium-denuded aortic rings contracted
with phenylephrine. Values are mean ± S.E.M. of n experiments performed on
preparations obtained from different animals. ⁄⁄⁄ indicates signiﬁcant difference
(P < 0.001) in pD2 value.
Fig. 4. Concentration–response curves for cis-[Ru(H-dcbpy)2(Cl)(NO

2 )] (DCBPY)
and sodium nitrite (NITRITE) in endothelium-denuded aortic rings contracted with
phenylephrine. Values are mean ± S.E.M. of n experiments performed on prepara-
tions obtained from different animals. ⁄⁄⁄ indicates signiﬁcant difference
(P < 0.001) in pD2 value for DCBPY vs. NITRITE.
Fig. 5. Concentration–response curves for cis-[Ru(H-dcbpy)2(Cl)(NO

2 )] (DCBPY) in
the absence or presence of the extracellular NO scavenger oxyhemoglobin (HBO2),
the nitroxyl NO (NO) scavenger L-cysteine or the radicalar NO (NO) scavenger
hydroxocobalamin. Endothelium-denuded aortic rings were contracted with
phenylephrine. Values are mean ± S.E.M. of n experiments performed on prepara-
tions obtained from different animals. ⁄⁄ indicates signiﬁcant difference (P < 0.01)
in pD2 value for DCBPY vs. DCBPY + L-CYSTEINE. ⁄⁄⁄ indicates signiﬁcant difference
(P < 0.001) in ME value for DCBPY vs. DCBPY + HYDROXYCOBALAMIN,
DCBPY + HBO2.
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at pH 5.4 (pD2: 5.91 ± 0.06; n = 10, P < 0.01) compared with pH 7.4
(pD2: 5.71 ± 0.06, P < 0.01, n = 9) and pH 9.4 (pD2: 5.66 ± 0.02,
P < 0.01, n = 9) (Fig. 3). A control of the acid and basic phosphate
buffer solutions employed in the preparation of the drug was car-
ried out, and it was observed that these solutions do not alter the
vascular tone. In addition, there are no differences in the maximum
relaxant effect induced by the compound at pH 5.4 (104.3 ± 1.0%,
n = 10), 7.4 (103.1 ± 1.2%, n = 9) and 9.4 (100.1 ± 1.8%; n = 9)
(Fig. 3).
The complex DCBPY is more potent (pD2: 5.71 ± 0.06, n = 9) than
NITRITE (pD2: 4.55 ± 0.09, n = 10, P < 0.001) as far as the relaxation
of aortic rings is concerned (see Fig. 4). The relaxation elicited by
DCBPY is inhibited by the extracellular NO scavenger oxyhemoglo-
bin (ME from 103.1 ± 1.2%, n = 9, to 14.1 ± 1.3%, n = 5, P < 0.001)
and by the (NO) species scavenger hydroxocobalamin (ME from
103.1 ± 1.2%, n = 9, to 14.2 ± 2.1%, n = 5, P < 0.001) (Fig. 5). On the
other hand, the NO scavenger L-cysteine decreases the potency
of DCBPY (pD2: 5.03 ± 0.09, P < 0.01, n = 6), but it does not change
the maximum relaxant effect (105.6 ± 19.0%; n = 6) (Fig. 5).
Inhibition of the enzyme guanylyl cyclase with ODQ blocks the
relaxation induced by DCBPY (ME from 103.1 ± 1.2%, n = 9, to
11.7 ± 1.5%, n = 8, P < 0.001) (Fig. 6). The non-selective K+ channelsFig. 3. Concentration–response curves for cis-[Ru(H-dcbpy)2(Cl)(NO)] (DCBPY)
solubilized in different pHs, in endothelium-denuded aortic rings contracted with
phenylephrine. A control experiment was carried out for acid and basic phosphate
buffer solution. Values are mean ± S.E.M. of n experiments performed on prepara-
tions obtained from different animals. ⁄⁄ indicates signiﬁcant difference (P < 0.01) in
the pD2 value for DCBPY (7.4) vs. DCBPY (5.4), DCBPY (9.4) vs. DCBPY (5.4).
Fig. 6. Concentration–response curves for cis-[Ru(H-dcbpy)2(Cl)(NO

2 )] (DCBPY) in
the absence or presence of ODQ (soluble guanylyl cyclase inhibitor) or TEA (non-
selective K+ channel blocker), in aortic rings endothelium-denuded contracted with
phenylephrine. Values are mean ± S.E.M. of n experiments performed on prepara-
tions obtained from different animals. ⁄ indicates signiﬁcant difference (P < 0.05) in
pD2 value for DCBPY vs. DCBPY + TEA. ⁄⁄⁄ indicates signiﬁcant difference (P < 0.001)
in ME value for DCBPY vs. DCBPY + ODQ.
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P < 0.05), without alterations in the maximum relaxant effect
(98.5 ± 2.5%, n = 7) (Fig. 6).Fig. 8. Decrease in cytosolic Ca2+ concentration ([Ca2+]c) induced by DCBPY (10 lm)
in vascular smooth muscle cells (VSMCs) from aortic rings of rats. %DFI indicates
the average of % [Ca2+]c decrease. Bars represent mean ± S.E.M. of n experiments
performed on preparations obtained from different rats. ⁄⁄⁄ indicates signiﬁcant
difference (P < 0.001) in %DFI value for NITRITE vs. DCBPY, SNP.Confocal microscopy
Fig. 7A evidences that in the aortic slice preparation, the DCBPY
complex diminishes the [Ca2+]c in the vascular smooth muscle
cells. This decrease in [Ca2+]c can be veriﬁed by fading of the inten-
sity of the red color after addition of DCBPY, as shown in Fig. 7. In
comparison, the decrease in [Ca2+]c in smooth muscle cells is great-
er for DCBPY (%DIF: 28.5 ± 1.5%; p < 0.001, n = 4) and SNP (%DIF:
25,30 ± 1,00%; p < 0.001, n = 3) as compared to NITRITE (%DIF:
13.47 ± 0.27%; n = 5) (Fig. 8).
Regarding the effect of released NO and the enhancement in
[NO]c, the compound DCBPY boosts the [NO]c in smooth muscle
cells, which can be seen from the increase in the intensity of the
red color after addition of DCBPY (Fig. 8). In comparison, the rise
in [NO]c is more pronounced for DCBPY (%DIF: 19.8 ± 1.8%, n = 5,
p < 0.001) and SNP (%DIF: 20.1 ± 3.0, n = 5, p < 0.01) compared with
NITRITE (%DIF: 13.1 ± 1.1, n = 4) (Fig. 9).Fig. 7. Representative images of slices of aortic rings preparation obtained by confocal mi
recorded. DCBPY was added after 80 s. (A) Cytosolic Ca2+ concentration ([Ca2+]c) in the va
3AM (10 lmol/L). (B) Cytosolic NO concentration ([NO]c) in the vascular smooth muscl
intensity of the colors indicate higher [Ca2+]c or [NO]c (as shown in the left bar).Discussion
The main ﬁnding of this study is that in its stable conﬁguration
(Ru-NO2 ) the ruthenium compound DCBPY is able to induce vascu-
lar relaxation. At physiological pH 7.4 and at pH 9.4, the NO+croscopy. The temporal effect of DCBPY (10 lm) on vascular smooth muscle cell was
scular smooth muscle cells (VSMCs) from aortic rings of rats, preloaded with FLUO-
e cells (VSMCs) from aortic rings of rats, preloaded with DAF-2 DA (5 lmol/L). The
Fig. 9. Increase in cytosolic NO concentration ([NO]c) induced by DCBPY (10 lm) in
vascular smooth muscle cells (VSMCs) from aortic rings of rats. %DFI indicates the
average of % [NO]c increase. Bars represent mean ± S.E.M. of n experiments
performed on preparations obtained from different rats. ⁄⁄⁄ indicates signiﬁcant
difference (P < 0.001) in %DFI value for DCBPY vs. NITRITE. ⁄⁄ indicates signiﬁcant
difference (P < 0.01) for SNP vs. NITRITE.
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Ru-NO+ conﬁguration is not stable in these conditions, but the
conﬁguration Ru-NO2 is. However, the Ru-NO
+ conﬁguration re-
mains stable for a long time at pH 5.4. Ruthenium complexes like
[Ru(bpy)2(L)(NO)] (bpy = 2,20-bipyridine, L = ligant, NO = nitric
oxide) can have different conﬁgurations, which are pH-dependent,
as depicted in Eq. (1) [30–32]. At pH 7.4, the Ru-NO+ conﬁguration
undergoes electrophilic attack by hydroxide, thereby generating
the Ru-NO2 conﬁguration [23]. Our results have indicated that
the compound cis-[Ru(H-dcbpy)2(Cl)(NO)] presents similar char-
acteristics to those of other ruthenium compounds described pre-
viously [30–32].
cis ½RuðH-dcbpyÞ2ðClÞðNOÞ ¢
OH
Hþ
cis ½RuðH-dcbpyÞ2ðClÞðNO2 Þ ð1Þ
When it comes to inducing relaxation of contracted aortas, the
stable Ru–NO2 conﬁguration from DCBPY is less potent than SNP.
Similar results have been achieved for other ruthenium com-
pounds that elicit vascular relaxation by NO release [16,23]. The
unstable Ru–NO conﬁguration is more potent in terms of prompt-
ing vascular relaxation compared with Ru–NO2 . These results
could suggest that the generation of NO is higher in the case of
the Ru–NO+ conﬁguration, compared with Ru–NO2 . Also, it could
be hypothesized that the Ru–NO2 conﬁguration behaves as a ni-
trite donor, considering that nitrite is less potent than NO when
induction of vascular relaxation is concerned [33–35]. In order to
verify this hypothesis, a relaxation curve was constructed for NI-
TRITE, which gave evidence that the DCBPY complex in the Ru–
NO2 conﬁguration elicited more potent relaxation compared with
NITRITE. Therefore, our data indicate that the DCBPY complex in
the Ru–NO2 conﬁguration is an NO generator instead of a nitrite
donor. Several mechanisms for in vivo conversion of NO2 to NO
have been identiﬁed including non-enzymatic disproportionation
at low pH [24], enzymatic conversion by xanthine oxidoreductase
[36] and reduction process by deoxyhemoglobin [26], myoglobin
[27], among others. Thus, stable ruthenium compounds can induce
vascular relaxation by conversion of nitrite to NO.
In this study and in previous works, it has been demonstrated
that NO can be generated by NO2 coordinated to ruthenium in
physiological conditions [22,23], thus supporting our hypothesis
that the stable Ru–NO2 conﬁguration of DCBPY is an NO generator.
However, the mechanism of nitrite conversion to NO need to be
investigated to nitrite coordinates to ruthenium.
As for aortas incubated with sGC inhibitor (ODQ), it was ob-
served that the relaxation induced by DCBPY is completely depen-
dent on sGC activation, suggesting that the compound DCBPY (Ru–
NO2 ) generates NO. NO can promote vascular relaxation by differ-ent mechanisms, which are either NO-cGMP dependent or NO-
cGMP independent. The main mechanism of NO with respect to
induction of relaxation involves activation of sGC, which catalyzes
the conversion of GTP into cGMP [37]. Acting as a second messen-
ger, cGMP activates a family of serine/threonine protein kinases
called cGMP-dependent protein kinases (PKG), which in turn in-
duces relaxation by decreasing [Ca2+]c and Ca2+ desensitization of
the actin-myosin contractile system [38]. In addition, other molec-
ular targets have been described to participate in the cGMP path-
way, including the activation of potassium channels [39,40]. The
NO cGMP-independent mechanisms have been reported in a num-
ber of studies, including those mentioning the direct activation of
K+ channels [5,6].
Potassium channels (K+ channels) play an important role in the
regulation of the vascular tone. Indeed, its activity is themain deter-
minant ofmembrane potential [40]. The K+ efﬂux, resulting from the
opening of K+ channels, causes hyperpolarization, inhibits voltage-
gated Ca2+ channels, and promotes relaxation. In our hands, the
non-selective K+ channel blocker (TEA) reduced the potency of
DCBPY in terms of inducing relaxation. Therefore, these results sug-
gest that the relaxation induced byDCBPYoccursmainly via theNO-
sGC-cGMPpathway, and the activation of K+ channels takes place by
the cGMP pathway or is due to the direct action of NO.
There are several NO redox forms, namely the authentic or rad-
icalar (NO), nitroxyl ion (NO), and nitrosonium (NO+). Using a
selective scavenger for the radicalar form (hydroxocobalamin)
and for the nitroxyl ion (L-cysteine) [8,41] it was veriﬁed that the
compound DCBPY generates the NO and NO forms. However,
our data suggest that NO is mainly generated by DCBPY. The extra-
cellular and non selective NO scavenger oxyhemoglobin [43] abol-
ishes relaxation induced by NO, evidencing that the compound
DCBPY generates NO in the extracellular medium. The reaction be-
tween NO and oxyhemoglobin is very fast, which does not allow
for detection of the biological effect due to NO [44], which can ex-
plain this result.
Some authors have shown that different NO forms can have dis-
tinct actions. Dierks & Burstyn [42] demonstrated that NO is the
only nitrogen monoxide redox form capable of activating sGC
and inducing vascular relaxation. Irvine et al. [41] stated that the
nitroxyl redox form activates K+ channel and prompts vascular
relaxation. Our results indicate that the compound DCBPY releases
the NO redox form, which activates sGC and promotes vascular
relaxation. In addition, K+ channel activation may be elicited by
the NO and/or NO redox forms, which would account for the low-
er sensitivity to relaxation induced by DCBPY in the presence of a
K+ channel blocker and a nitroxyl scavenger.
Confocal microscopy evidenced that DCBPY, SNP, and NITRITE
diminish [Ca2+]c, suggesting that vascular relaxation occurs in re-
sponse to a reduction in [Ca2+]c. Similar results have been obtained
with other NO donors [23,29,35]. The decrease in [Ca2+]c elicited
by DCBPY and SNP is similar, but that prompted by NITRITE is low-
er. For this reason, we believe that these effects on [Ca2+]c are re-
lated to different increases in [NO]c induced by DCBPY, SNP, and
NITRITE, which are inversely proportional to the response in the
case of decreased [Ca2+]c. Considering that the concentration that
induced the maximum relaxant effect on vascular reactivity was
used for our experiments, we had expected to obtain the same
magnitude of effect on the lowering of [Ca2+]c. Taken together,
these results suggest that part of the effect of NITRITE on vascular
relaxation is due to an independent mechanism for [Ca2+]c reduc-
tion, which could take place via Ca2+ desensitization of the actin-
myosin contractile system.
In conclusion, our results demonstrate that the compound
DCBPY (Ru-NO2 ) is an NO generator that induces relaxation of
rat aortic rings due to a decrease in [Ca2+]c. The vascular smooth
muscle relaxation depends mainly on sGC activation.
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